ABSTRACT
Hepatitis C virus-infected (HCV+) adults evidence increased rates of psychiatric and cognitive difficulties. This is the first study to use functional magnetic resonance imaging (fMRI) to examine brain activation in untreated HCV+ adults. To determine whether, relative to non-infected controls (CTLs), HCV+ adults exhibit differences in brain activation during a delay discounting task (DDT), a measure of one's tendency to choose smaller immediate rewards over larger delayed rewards-one aspect of impulsivity. Twenty adults with HCV and 26 CTLs completed an fMRI protocol during the DDT. Mixed effects regression analyses of hard versus easy trials of the DDT showed that, compared with CTLs, the HCV+ group exhibited less activation in the left lateral occipital gyrus, precuneus, and superior frontal gyrus. There were also significant interactive effects for hard-easy contrasts in the bilateral medial frontal gyrus, left insula, left precuneus, left inferior parietal lobule, and right temporal occipital gyrus; the CTL group evidenced a positive relationship between impulsivity and activation, while the HCV+ group exhibited a negative relationship. Within the HCV+ group, those with high viral load chose immediate rewards more often than those with low viral load, regardless of choice difficulty; those with low viral load chose immediate rewards more often on hard choices relative to easy choices. Results show that HCV+ patients exhibit greater impulsive behavior when presented with difficult choices, and impulsivity is negatively related to activation in regions important for cognitive control. Thus, interventions that decrease impulsive choice may be warranted with some HCV+ patients.
Subject(s)
Brain/physiopathology , Delay Discounting/physiology , Hepatitis C/psychology , Adult , Aged , Female , Hepatitis C/complications , Hepatitis C/physiopathology , Humans , Magnetic Resonance Imaging , Male , Middle AgedABSTRACT
Higher levels of cognitive reserve (CR) can be protective against the neuropsychological manifestation of neural injury across a variety of clinical disorders. However, the role of CR in the expression of neurocognitive deficits among persons infected with the hepatitis C virus (HCV) is not well understood. Thirty-nine HCV-infected participants were classified as having either high (n = 19) or low (n = 20) CR based on educational attainment, oral word reading, and IQ scores. A sample of 40 demographically comparable healthy adults (HA) was also included. All participants completed the Neuropsychological Assessment Battery, Delis-Kaplan Executive Function System, and Behavioral Rating Inventory of Executive Function, Adult Version (BRIEF-A). Linear regression analyses, controlling for gender, depression, and lifetime substance use disorders, found significant effects of HCV/CR group on verbal fluency, executive functions, and daily functioning T scores, but not in learning or the BRIEF-A. Pairwise comparisons revealed that the HCV group with low CR performed significantly below the HCV high CR and HA cohorts, who did not differ from one another. Findings indicate that higher levels of CR may be a protective factor in the neurocognitive and real-world manifestation of neural injury commonly associated with HCV infection.
Subject(s)
Cognitive Reserve/physiology , Hepacivirus , Hepatitis C/psychology , Activities of Daily Living , Adult , Attention/physiology , Case-Control Studies , Educational Status , Executive Function/physiology , Female , Hepatitis C/physiopathology , Hepatitis C/virology , Humans , Linear Models , Male , Memory/physiology , Middle Aged , Neuropsychological Tests , Task Performance and AnalysisABSTRACT
PURPOSE: To examine self-awareness in chronic traumatic brain injury (TBI) by cognitive domain, compare domain-specific self-awareness to global impaired self-awareness, and evaluate change in self-appraisal of cognitive ability from before to after neuropsychological testing. METHOD: Secondary analysis of a cross-sectional cohort of 59 participants with chronic TBI. We grouped participants as underestimators, fair estimators, and overestimators of their memory and executive functioning. We then compared these groups by global self-awareness measures, other clinical measures, and pre- to-posttest change in self-appraisal of cognitive performance. RESULTS: Analyses revealed no significant differences in global self-awareness measures or depression between fair or underestimators and overestimators in Memory or Executive Function Domains. Only 12.50% of participants in the Memory Composite Domain and 6.89% of participants in the Executive Function Composite Domain changed their pre- to postneuropsychological test self-appraisal of cognitive ability. CONCLUSION: This study revealed most participants did not change their self-appraisal in response to completing neuropsychological testing alone. In conjunction with our findings that suggest global self-awareness measures may not adequately capture domain-specific self-awareness deficits in chronic TBI, this study provides support for development of targeted self-awareness assessment tools and the need for structured feedback, rather than naturalistic feedback alone, to improve self-awareness in chronic TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
Subject(s)
Brain Injuries, Traumatic , Awareness , Brain Injuries, Traumatic/complications , Cognition , Cross-Sectional Studies , Executive Function , Humans , Neuropsychological Tests , PerceptionABSTRACT
A concussion knowledge survey was completed by 561 rehabilitation professionals across a wide range of disciplines in a nationwide rehabilitation hospital system. Item questions were structured to reflect key areas of concussion knowledge targeted in a prior consensus statement. The vast majority of staff provided responses consistent with the current concussion literature regarding concussion diagnosis and symptom presentation immediately after concussion. Greater variability was seen for items assessing beliefs about the typical recovery from concussion, best care practices, and long-term effects from concussion. Factors such as profession, years of experience, and work with concussion or traumatic brain injury were not consistently related to better performance on the survey. Prior concussion-focused education/training was related to better survey performance. This survey highlights the pressing need to educate frontline health providers regarding concussion recovery and best care practices.
ABSTRACT
OBJECTIVE: To prospectively evaluate for changes in objective cognitive performance (attention, memory, and executive function) and psychiatric symptom severity (depression, anxiety, fatigue, and pain) in patients before, during and after interferon-alpha based therapy (IFN) for chronic hepatitis C virus infection (HCV). METHODS: 33 HCV+ adults were evaluated two months before IFN initiation (baseline), three months into IFN, and six months following IFN termination (IFN+ Group). 31 HCV+ adults who did not undergo IFN therapy were evaluated at baseline and six months later (IFN- Group). At each evaluation, participants completed the Neuropsychological Assessment Battery (NAB) Attention, Memory and Executive Functions Modules, the Beck Depression Inventory, Second Edition (BDI), Generalized Anxiety Disorder Inventory (GADI), Fatigue Severity Scale (FSS), and Brief Pain Inventory (BPI). RESULTS: Compared with the IFN- Group, the IFN+ Group experienced significantly (p<0.050) increased symptoms of depression, anxiety, fatigue and pain during IFN therapy relative to baseline. In the IFN+ Group, psychiatric symptoms generally returned to baseline levels following IFN termination. Sustained viral response was associated with significantly lower depression and fatigue. No significant changes in cognitive performance were observed. CONCLUSIONS: During IFN, patients with HCV evidence significantly increased psychiatric symptoms, including symptoms of depression, anxiety, fatigue and pain. These psychiatric symptoms are generally short-term and remit following IFN termination, with increased benefit if viral clearance is achieved. However, IFN is not associated with significant declines in objective cognitive performance during or following IFN.
Subject(s)
Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/psychology , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Adult , Aged , Anxiety/etiology , Cognition/drug effects , Comorbidity , Depression/etiology , Fatigue/etiology , Female , Humans , Longitudinal Studies , Male , Middle Aged , Neuropsychological Tests , Pain/etiology , Psychiatric Status Rating Scales , Severity of Illness Index , Viral Load/drug effectsABSTRACT
BackgroundThe purpose of this study was to characterize hepatitis C virus (HCV)-associated differences in the expression of 47 inflammatory factors and to evaluate the potential role of peripheral immune activation in HCV-associated neuropsychiatric symptoms-depression, anxiety, fatigue, and pain. An additional objective was to evaluate the role of immune factor dysregulation in the expression of specific neuropsychiatric symptoms to identify biomarkers that may be relevant to the treatment of these neuropsychiatric symptoms in adults with or without HCV. MethodsBlood samples and neuropsychiatric symptom severity scales were collected from HCV-infected adults (HCV+, n = 39) and demographically similar noninfected controls (HCV-, n = 40). Multi-analyte profile analysis was used to evaluate plasma biomarkers. ResultsCompared with HCV- controls, HCV+ adults reported significantly (P < 0.050) greater depression, anxiety, fatigue, and pain, and they were more likely to present with an increased inflammatory profile as indicated by significantly higher plasma levels of 40% (19/47) of the factors assessed (21%, after correcting for multiple comparisons). Within the HCV+ group, but not within the HCV- group, an increased inflammatory profile (indicated by the number of immune factors > the LDC) significantly correlated with depression, anxiety, and pain. Within the total sample, neuropsychiatric symptom severity was significantly predicted by protein signatures consisting of 4-10 plasma immune factors; protein signatures significantly accounted for 19-40% of the variance in depression, anxiety, fatigue, and pain. ConclusionsOverall, the results demonstrate that altered expression of a network of plasma immune factors contributes to neuropsychiatric symptom severity. These findings offer new biomarkers to potentially facilitate pharmacotherapeutic development and to increase our understanding of the molecular pathways associated with neuropsychiatric symptoms in adults with or without HCV.
Subject(s)
Anxiety/blood , Cytokines/analysis , Depression/blood , Fatigue/blood , Hepatitis C, Chronic/blood , Immunoproteins/analysis , Pain/blood , Adult , Biomarkers , Female , Humans , Male , Middle Aged , Severity of Illness IndexABSTRACT
We aimed to determine whether group-based Cognitive Strategy Training (CST) for combat veterans with mild cognitive disorder and a history of traumatic brain injury (TBI) has significant posttreatment effects on self-reported compensatory strategy usage, functioning, and psychiatric symptoms. Participants included 21 veterans returning from conflicts in Iraq or Afghanistan with a diagnosis of Cognitive Disorder, Not Otherwise Specified and a history of combat-related TBI. Participants attended 6- to 8-week structured CST groups designed to provide them training in and practice with a variety of compensatory cognitive strategies, including day planner usage. Of the participants, 16 completed pre- and posttreatment assessment measures. Following CST, participants reported significantly increased use of compensatory cognitive strategies and day planners; an increased perception that these strategies were useful to them; increased life satisfaction; and decreased depressive, memory, and cognitive symptom severity. Group-based CST is a promising intervention for veterans with mild cognitive disorder, and randomized controlled trials are required to further evaluate its efficacy.